TargetMol

SLV-310

Product Code:
 
TAR-T28809
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28809-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28809-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28809-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
SLV-310 is a potent dopamine D2 receptor antagonist and 5-HT reuptake receptor inhibitor.
CAS:
264869-71-8
Formula:
C25H24FN3O2
Molecular Weight:
417.484
Purity:
0.98
SMILES:
Fc1ccc2[nH]cc(C3=CCN(CCCCN4C(=O)c5ccccc5C4=O)CC3)c2c1

References

1. van Hes R, Smid P, Stroomer CN, Tipker K, Tulp MT, van der Heyden JA, McCreary AC, Hesselink MB, Kruse CG. SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition. Bioorg Med Chem Lett. 2003 Feb 10;13(3):405-8. PubMed PMID: 12565939. 2. Lange JH, Reinders JH, Tolboom JT, Glennon JC, Coolen HK, Kruse CG. Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. J Med Chem. 2007 Oct 18;50(21):5103-8. PubMed PMID: 17880057. 3. Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology. 2008 Nov;55(6):1056-65. doi: 10.1016/j.neuropharm.2008.05.025. Review. PubMed PMID: 18621404.